| 1 |
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. Ca-Cancer J Clin, 2015, 65(2): 87-108.
|
| 2 |
Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017[J]. Ca-Cancer J Clin, 2017, 67(1): 7-30.
|
| 3 |
Monteiro J, Fodde R. Cancer stemness and metastasis: therapeutic consequences and perspectives[J]. Eur J Cancer, 2010, 46(7): 1198-1203.
|
| 4 |
Fazi F, Fontemaggi G. MicroRNAs and lymph node metastatic disease in lung cancer[J]. Thorac Surg Clin, 2012, 22(2): 167-175.
|
| 5 |
Schuler M, Wu Y, Hirsh V, et al. First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases[J]. J Thorac Oncol, 2016, 11(3): 380-390.
|
| 6 |
Tabouret E, Chinot O, Metellus P, et al. Recent trends in epidemiology of brain metastases: an overview[J]. Anticancer Res, 2012, 32(11): 4655-4662.
|
| 7 |
Dawe D, Greenspoon J, Ellis P. Brain metastases in non-small-cell lung cancer[J]. Clin Lung Cancer, 2014, 15(4): 249-257.
|
| 8 |
Penner MR, Mizumori SJ. Neural systems analysis of decision making during goal-directed navigation[J]. Prog Neurobiol, 2012, 96(1): 96-135.
|
| 9 |
Zhuang H, Yuan Z, Wang J, et al. Phase Ⅱ study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma[J]. Drug Des Devel Ther, 2013, 7: 1179-1186.
|
| 10 |
曾银朵，丁林潇潇，陈丽昆. 非小细胞肺癌脑转移治疗进展[J]. 国际肿瘤学杂志，2011, 38(7): 537-540.
|
| 11 |
Mahmood U, Kwok Y, Regine WF, et al. Whole-brain irradiation for patients with brain metastases: still the standard of care[J]. Lancet Oncol, 2010, 11(3): 221-222, 223.
|
| 12 |
Bowden G, Kano H, Caparosa E, et al. Gamma knife radiosurgery for the management of cerebral metastases from non-small cell lung cancer[J]. J Neurosurg, 2015, 122(4): 766-772.
|
| 13 |
Yamamoto M, Serizawa T, Shuto T, et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study[J]. Lancet Oncol, 2014, 15(4): 387-395.
|
| 14 |
Kim SY, Hong CK, Kim TH, et al. Efficacy of surgical treatment for brain metastasis in patients with non-small cell lung cancer[J]. Yonsei Med J, 2015, 56(1): 103-111.
|
| 15 |
Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain[J]. N Engl J Med, 1990, 322(8): 494-500.
|
| 16 |
Kozower BD, Larner JM, Detterbeck FC, et al. Special treatment issues in non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines[J]. Chest, 2013, 143(5 Suppl): e369S-e399S.
|
| 17 |
Tsao M, Xu W, Sahgal A. A meta-analysis evaluating stereotactic radiosurgery, whole-brain radiotherapy, or both for patients presenting with a limited number of brain metastases[J]. Cancer-Am Cancer Soc, 2012, 118(9): 2486-2493.
|
| 18 |
He XY, Liu BY, Yao WY, et al. Serum DJ-1 as a diagnostic marker and prognostic factor for pancreatic cancer[J]. J Dig Dis, 2011, 12(2): 131-137.
|
| 19 |
Tang N, Guo J, Zhang Q, et al. Greater efficacy of chemotherapy plus bevacizumab compared to chemo-and targeted therapy alone on non-small cell lung cancer patients with brain metastasis[J]. Oncotarget, 2016, 7(3): 3635-3644.
|
| 20 |
Besse B, Lasserre SF, Compton P, et al. Bevacizumab safety in patients with central nervous system metastases[J]. Clin Cancer Res, 2010, 16(1): 269-278.
|
| 21 |
Bearz A, Garassino I, Tiseo M, et al. Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer[J]. Lung Cancer, 2010, 68(2): 264-268.
|
| 22 |
Raizer JJ, Rademaker A, Evens AM, et al. Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma[J]. Cancer-Am Cancer Soc, 2012, 118(15): 3743-3748.
|
| 23 |
Ma LH, Li G, Zhang HW, et al. Hypofractionated stereotactic radiotherapy with or without whole-brain radiotherapy for patients with newly diagnosed brain metastases from non-small cell lung cancer[J]. J Neurosurg, 2012, 117 Suppl: 49-56.
|
| 24 |
Herbst RS, Heymach JV, Lippman SM. Lung cancer[J]. N Engl J Med, 2008, 359(13): 1367-1380.
|
| 25 |
Han JY, Park K, Kim SW, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung[J]. J Clin Oncol, 2012, 30(10): 1122-1128.
|
| 26 |
Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial[J]. Lancet Oncol, 2012, 13(3): 239-246.
|
| 27 |
Sequist LV, Yang JC, Yamamoto N, et al. Phase Ⅲ study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations[J]. J Clin Oncol, 2013, 31(27): 3327-3334.
|
| 28 |
Chen Y, Yang J, Li X, et al. First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor alone or with whole-brain radiotherapy for brain metastases in patients with EGFR-mutated lung adenocarcinoma[J]. Cancer Sci, 2016, 107(12): 1800-1805.
|
| 29 |
Zheng H, Liu QX, Hou B, et al. Clinical outcomes of WBRT plus EGFR-TKIs versus WBRT or TKIs alone for the treatment of cerebral metastatic NSCLC patients: a meta-analysis[J]. Oncotarget, 2017, 8(34): 57356-57364.
|
| 30 |
Jiang T, Su C, Li X, et al. EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases[J]. J Thorac Oncol, 2016, 11(10): 1718-1728.
|
| 31 |
Janne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer [J]. N Engl J Med, 2015, 372(18): 1689-1699.
|
| 32 |
Ahn MJ, Kim DW, Cho BC, et al. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study[J]. Lancet Respir Med, 2017, 5(11): 891-902.
|
| 33 |
Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK[J]. J Clin Oncol, 2009, 27(26): 4247-4253.
|
| 34 |
Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer[J]. N Engl J Med, 2013, 368(25): 2385-2394.
|
| 35 |
Chamberlain MC, Baik CS, Gadi VK, et al. Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma[J]. Neuro Oncol, 2017, 19(1): 1-24.
|
| 36 |
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy [J]. Nat Rev Cancer, 2012, 12(4): 252-264.
|
| 37 |
Schvartsman G, Ferrarotto R, Massarelli E. Checkpoint inhibitors in lung cancer: latest developments and clinical potential[J]. Ther Adv Med Oncol, 2016, 8(6): 460-473.
|
| 38 |
Goldberg SB, Gettinger SN, Mahajan A, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial[J]. Lancet Oncol, 2016, 17(7): 976-983.
|